

RESEARCH GROUP
Clinical and Translational Research in Pharmacogenetics
University of Extremadura, Spain

The research group "Clinical and Translational Research in Pharmacogenetics" led by Prof. Adrián Llerena is situated at the Extremadura University Hospital and Medical School in Badajoz (Spain) as a part of the Clinical Research Center CICAB.

The group is mainly focused on Biomedical, Clinical Research. More specifically, the developed research is related to:

- Pharmacogenetics and clinical pharmacogenomics;
- Clinical Trials and drug monitorings;
- Psychobiology and clinical psychopharmacology.
- Schizophrenia epidemiology and pharmacoepidemiology;

Moreover, this group coordinates the Iberoamerican Network of Pharmacogenetics and Pharmacogenomics (RIBEF), which is composed by more than forty groups of research from Spain, Portugal and Iberoamerica.

All of the activities are carried out through several national and international projects, within a collaborative framework with several research groups, not only from Spain, but also from many other countries. Remarkable results are obtained, which have been published in a broad number of publications within prestigious international journals.

Members of the group

- **Adrián Llerena** (Director of Clinical Research Centre (CICAB) at Extremadura University Hospital //Professor at the Faculty of Medicine, Universidad de Extremadura).
- **Eva M^a PeñasLledó** (Professor at Universidad de Extremadura).
- **Humberto Fariñas Seijas**(Biostatistics BSc degree,PhD,CICAB).
- **Pedro Dorado Hernández** (Associate Professor at Universidad de Extremadura).
- **Macarena Cáceres León** (Associate Professor at Universidad de Extremadura).
- **Idilio González Martínez** (Psychiatrist MD PhD, Extremadura Health System).
- **Alfredo de la Rubia Martínez** (Psychiatrist MD PhD, Extremadura Health System).
- **Antonio P. González González**(Psychiatrist MD PhD, Extremadura Health System).
- **Jesús Coboleda Polo** (Family Medicine MD PhD,Extremadura Health System).
- **Fernando de Andrés Segura** (Postdoc Researcher ISCIII"Sara Borrell" program,CICAB).
- **María Eugenia González Naranjo** (Predoctoral Assistant Researcher,CICAB).
- **Paloma López Moyano** (Clinical Trials Coordinator,CICAB).
- **Aurea Delgado Regalado** (PredoctoralStudent, Universidad de Extremadura).
- **Alicia Gallego Aguilera** (Predoctoral Student, Universidad de Extremadura).
- **Beatriz Grillo Durán** (Lab Technician, CICAB).
- **Inés M^a López Ferrer** (Lab Technician, Universidad de Extremadura).
- **Carolina Céspedes Garro**(Predoctoral Predoctoral Student, Universidad de Costa Rica).
- **Fernanda Soares Rodrigues Santos** (Predoctoral Assistant Researcher, Universidade Federal de Minas Gerais).

2012-2014 PUBLICATIONS

2012

2012.01. PEÑAS-LLEDÓ EM, DORADO P, AGÜERA Z, GRATACÓS M, ESTIVILL X, FERNÁNDEZ-ARANDA F, LLERENA A. CYP2D6 polymorphism in patients with eating disorders.

Pharmacogenomics J. 2012 Apr;12(2):173-5.

2012.02. LLERENA A, DORADO P, RAMÍREZ R, GONZÁLEZ I, ALVAREZ M, PEÑAS-LLEDÓ EM, PÉREZ B, CALZADILLA LR. CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans.

Pharmacogenomics J. 2012 Apr;12(2):176-83.

2012.03. DORADO P, HERAS N, MACHÍN E, HERNÁNDEZ F, TERAN E, LLERENA A. CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population.

Eur J Clin Pharmacol. 2012 May;68(5):637-44.

2012.04. PEÑAS-LLEDÓ EM, BLASCO-FONTECILLA H, DORADO P, VAQUERO-LORENZO C, BACA-GARCÍA E, LLERENA A. CYP2D6 and the severity of suicide attempts.

Pharmacogenomics. 2012 Jan;13(2):179-84.

2012.05. RODEIRO I, REMÍREZ-FIGUEREDO D, GARCÍA-MESA M, DORADO P, LLERENA A; CEIBA.FP CONSORTIUM OF THE IBERO-AMERICAN NETWORK OF PHARMACOGENETICS AND PHARMACOGENOMICS RIBEF. Pharmacogenetics in Latin American populations: regulatory aspects, application to herbal medicine, cardiovascular and psychiatric disorders.

Drug Metabol Drug Interact. 2012;27(1):57-60.

2012.06. DORADO P, MACHÍN E, DE ANDRÉS F, GONZÁLEZ-NARANJO ME, PEÑAS-LLEDÓ EM, LLERENA A AND CEIBA.FP CONSORTIUM OF THE IBERO-AMERICAN NETWORK OF PHARMACOGENOMICS RIBEF. Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes.

Drug Metabol Drug Interact. 2012;27(4):217-33.

2012.07. DORADO P, DE ANDRÉS F, GONZÁLEZ-NARANJO ME, PEÑAS-LLEDÓ EM, GONZÁLEZ I, GONZÁLEZ AP, DE LA RUBIA A, LLERENA A. High-performance liquid chromatography method using ultraviolet detection for the quantification of aripiprazole and dehydroaripiprazole in psychiatric patients.

Drug Metabol Drug Interact. 2012;27(3):165-70.

2012.08. DORADO P, BELTRÁN L, MACHÍN E, HERNÁNDEZ F, PEÑAS-LLEDÓ EM, TERÁN E, LLERENA A. Losartan hydroxylation phenotype in an Ecuadorian population: influence of CYP2C9 genetic polymorphism, habits and gender.

Pharmacogenomics. 2012 Nov;13(15):1711-7.

2012.09. MAS S, LLERENA A, SAÍZ J, BERNARDO M, LAFUENTE A. Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. **Pharmacogenomics. 2012 Nov;13(15):1773-82.**

2012.10. PEÑAS-LLEDÓ EM, GONZÁLEZ I, DORADO P, PÉREZ B, CALZADILLA LR, ALVÁREZ M, NARANJO MEG, LLERENA A, CEIBA.FP Consortium of the Ibero-American Network of Pharmacogenomics RIBEF. Eating Disorder Symptoms and CYP2D6 Variation in Cuban Healthy Females: A Report from the Ibero-American Network of Pharmacogenetics.

Current Pharmacogenomics and Personalized Medicine, 2012.

2012.11. PEÑAS-LLEDO EM, LLERENA A. CYP2D6 Ultrarapid Metabolism and Suicide
[Journal of Pharmacogenomics and Pharmacoproteomics. 2011. 3-2.](#)

2012.12. ESPINOSA-GARCÍA J, MARTELL-CLAROS N, LLERENA A, FERNÁNDEZ-BERGÉS D.
[Pharmacological compliance in the treatment of arterial hypertension. A review of studies published
between 1975 and 2011].
[Semergen. 2012 Jul-Aug;38\(5\):292-300. PMID: 23544776.](#)

2013.01. ALMOGUERA B, RIVEIRO-ALVAREZ R, LOPEZ-CASTROMAN J, DORADO P, VAQUERO-LORENZO C, FERNANDEZ-PIQUERAS J, LLERENA A, ABAD-SANTOS F, BACA-GARCÍA E, DAL-RÉ R, AYUSO C. Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population.

Pharmacogenomics J. 2013 Apr;13(2):197-204.

2013.02. DORADO P, LÓPEZ-TORRES E, PEÑAS-LLEDÓ EM, MARTÍNEZ-ANTÓN J, LLERENA A. Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms.

Pharmacogenomics J. 2013 Aug;13(4):359-61.

2013.03. PEÑAS-LLEDÓ EM, TREJO H, DORADO P, ORTEGA A, JUNG H, ALONSO E, NARANJO ME, LÓPEZ-LÓPEZ M, LLERENA A. CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients.

Mol Psychiatry. 2013 Feb;18(2):266.

2013.04. GONZÁLEZ-VACAREZZA N, ABAD-SANTOS F, CARCAS-SANSUAN A, DORADO P, PEÑAS-LLEDÓ E, ESTÉVEZ-CARRIZO F, LLERENA A. Use of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6.

Pharmacogenomics J. 2013 Oct;13(5):452-5.

2013.05. BERNARDO M, BIOQUE M, PARELLADA M, SAIZ RUIZ J, CUESTA MJ, LLERENA A, SANJUÁN J, CASTRO-FORNIELES J, ARANGO C, CABRERA B; PEPS GROUP. Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs).

Rev Psiquiatr Salud Ment. 2013 Jan;6(1):4-16.

2013.06. LÓPEZ M, DORADO P, ORTEGA A, PEÑAS-LLEDÓ E, MONROY N, SILVA-ZOLEZZI I, COBALEDA J, GALLEGU-AAGUILERA A, ALONSO ME, LLERENA A. Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations.

Mol Biol Rep. 2013 Apr;40(4):3187-92.

2013.07. LLERENA A, BEREZ R, PEÑAS-LLEDÓ E, SÜVEGES A, FARIÑAS H. Pharmacogenetics of clinical response to risperidone.

Pharmacogenomics. 2013 Jan;14(2):177-94.

2013.08. SOSA-MACÍAS M, LAZALDE-RAMOS BP, GALAVIZ-HERNÁNDEZ C, RANGEL-VILLALOBOS H, SALAZAR-FLORES J, MARTÍNEZ-SEVILLA VM, MARTÍNEZ-FIERRO ML, DORADO P, WONG M-L, LICINIO J, LLERENA A. Influence of admixture components on CYP2C9*2 allele frequency in Indigenous groups from Northwest Mexico.

Pharmacogenomics J. 2013 Dec;13(6):567-72.

2013.09. BLASCO-FONTECILLA H, PEÑAS-LLEDÓ EM, VAQUERO-L. C, DORADO P, SAÍZ-RUIZ J, LLERENA A, BACA-GARCIA E. CYP2D6 polymorphism, mental and personality disorders in suicide attempters.

J PersDisord. 2013 Feb 11.[Epub ahead of print].

2013.10. LLERENA A. Clinical pharmacology of drug metabolism and drug interactions: clinical, interethnic and regulatory aspects.

Drug Metabol Drug Interact. 2013;28(1):1-3.

2013.11. PEÑAS-LLEDÓ EM, NARANJO ME, LLERENA A. Impact of cytochrome P450 genes on suicide

attempt and risk.

[Eur Arch Psychiatry ClinNeurosci. 2013 Dec;263\(8\):703-4.](#)

2013.12. DORADO P, PEÑAS-LLEDÓ E, LLERENA A. Highlights from the latest articles in CYP2D6 activity and breast cancer outcomes during treatment with tamoxifen.

[Pharmacogenomics. 2013 Apr;14\(6\):604-6.](#)

2013.13. ÖZDEMİR V, LLERENA A, MCKINNON R, SRIVASTAVA S, DOVE ES, FERGUSON LR, MASELLIS M, WARNICH L. CPPM 2013 Onward: Building a Socio-Technical GPS for Global Personalized Medicine.

[Current Pharmacogenomics and Personalized Medicine 11 \(2\): 87-92.](#)

2013.14. STATHOPOULOU MG, MONTEIRO P, SHAHABI P, PEÑAS-LLEDÓ EM, EL SHAMIEH S, SILVA SANTOS L, THILLY N, SIEST G, LLERENA A, VISVIKIS-SIEST S. Newly identified synergy between clopidogrel and calcium-channel blockers for blood pressure regulation possibly involves CYP2C19 rs4244285.

[Int J Cardiol. 2013 Oct 3;168\(3\):3057-8.](#)

2013.15. PEÑAS-LLEDÓ EM, AGÜERA Z, SÁNCHEZ I, GUNNARD K, JIMÉNEZ-MURCIA S, FERNÁNDEZ-ARANDA F. Differences in cognitive behavioral therapy dropout rates between bulimia nervosa subtypes based on drive for thinness and depression.

[PsychotherPsychosom. 2013;82\(2\):125-6.](#)

2013.16. TRACE SE, BAKER JH, PEÑAS-LLEDÓ E, BULIK CM. The genetics of eating disorders.

[Annu Rev Clin Psychol. 2013 Mar 28;9:589-620.](#)

2013.17. GONZÁLEZ-VACAREZZA N, DORADO P, PEÑAS-LLEDÓ EM, FARIÑAS H, ESTÉVEZ-CARRIZO FE, LLERENA A. MDR-1 genotypes and quetiapine pharmacokinetics in healthy volunteers.

[Drug Metabol Drug Interact. 2013;28\(3\):163-6.](#)

2013.18. DE ANDRÉS F, SOSA-MACÍAS M, LAZALDE-RAMOS BP, NARANJO ME, TARAZONA-SANTOS E, LLERENA A; CEIBA.FP Consortium of the Ibero-American Network of Pharmacogenetics and Pharmacogenomics RIBEF. Evaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: the CEIBA cocktail.

[Drug Metabol Drug Interact. 2013;28\(3\):135-46.](#)

2013.19. ALMOGUERA B, RIVEIRO-ALVAREZ R, LOPEZ-CASTROMAN J, DORADO P, VAQUERO-LORENZO C, FERNANDEZ-PIQUERAS J, LLERENA A, ABAD-SANTOS F, BACA-GARCÍA E, DAL-RÉ R, AYUSO C; SPANISH CONSORTIUM OF PHARMACOGENETICS RESEARCH IN SCHIZOPHRENIA. CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment.

[Pharmacogenet Genomics. 2013 Nov;23\(11\):627-30.](#)

2013.20. SOSA-MACÍAS M, LLERENA A. Cytochrome P450 genetic polymorphisms of Mexican indigenous populations.

[Drug Metabol Drug Interact. 2013;28\(4\):193-208.](#)

2013. 21. ALBUQUERQUE J, RIBEIRO C, NARANJO MEG, LLERENA A, GRAZINA M & CEIBA.FP Consortium of the Ibero-american Network of Pharmacogenetics and Pharmacogenomics RIBEF. Characterization of CYP2D6 genotypes and metabolic profiles in the Portuguese population: pharmacogenetic implications.

[Personalized Medicine. 2013; 10\(7\): 709-718.](#)

2013.22. PEÑAS-LLEDÓ EM, LLERENA A. CYP2D6 genetic polymorphism and psychiatry patients' hospitalization period.

[Biomark Med. 2013 Dec;7\(6\):915-6.](#)

2013.23. LLERENA A, DORADO P, RAMÍREZ R, CALZADILLA LR, PEÑAS-LLEDÓ E, ALVAREZ M, NARANJO ME, GONZÁLEZ I, PÉREZ B; CEIBA CONSORTIUM OF THE IBERO-AMERICAN NETWORK OF PHARMACOGENETICS & PHARMACOGENOMICS RIBEF. CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers.

[Pharmacogenomics. 2013 Dec;14\(16\):1973-7.](#)

2014

Book chapter:

2014.01. LLERENA A, DORADO P, GONZÁLEZ-NARANJO ME, PEÑAS-LLEDO EM.
CYP2D6 ethnic variability in Hispanics.

CYP2D6: Genetics, Pharmacology and Clinical Relevance. Editor: Pierre Baumann

ISBN: 978-1-78084-462-6. Editorial: Future Medicine Ltd.

2014.02. LLERENA A, FARIÑAS H, GONZALEZ-VACAREZZA N, CÁCERES MC.

Regulación farmacogenética y farmacogenómica en la EMA.

Libro Fundación 2000 En: Medicina Personalizada. Aspectos Científicos, Bioéticos y Jurídicos (Sánchez-Caro J, Abellán F) Fundación Salud 2000, Madrid 2014. Páginas: 164-183.

ISBN: 978-84-695-8758-4.

Articles:

2014.01. JARAMILLO NM, GALINDO IF, VÁZQUEZ AO, COOK HJ, LLERENA A, LÓPEZ M.

Pharmacogenetic potential biomarkers for carbamazepine adverse drug reactions and clinical response.

Drug Metabol Drug Interact. 2014 Jan 9:1-13.

2014.02. OZDEMIR V, KOLKER E, HOTEZ PJ, MOHIN S, PRAINSACK B, WYNNE B, VAYENA E, COŞKUN Y, DERELI T, HUZAIR F, BORDA-RODRIGUEZ A, BRAGAZZI NL, FARIS J, RAMESAR R, WONKAM A, DANDARA C, NAIR B, LLERENA A, KILIÇ K, JAIN R, REDDY PJ, GOLLAPALLI K, SRIVASTAVA S, KICKBUSCH I. Ready to put metadata on the post-2015 development agenda? Linking data publications to responsible innovation and science diplomacy.

OMICS. 2014 Jan;18(1):1-9.

2014.03. KOLKER E, OZDEMIR V, MARTENS L, HANCOCK W, ANDERSON G, ANDERSON N, AYNACIOGLU S, BARANOVA A, CAMPAGNA SR, CHEN R, CHOINIÈRE J, DEARTH SP, FENG WC, FERGUSON L, FOX G, FRISHMAN D, GROSSMAN R, HEATH A, HIGDON R, HUTZ MH, JANKO I, JIANG L, JOSHI S, KEL A, KEMNITZ JW, KOHANE IS, KOLKER N, LANCET D, LEE E, LI W, LISITSA A, LLERENA A, MACNEALY-KOCH C, MARSHALL JC, MASUZZO P, MAY A, MIAS G, MONROE M, MONTAGUE E, MOONEY S, NESVIZHSKII A, NORONHA S, OMENN G, RAJASIMHA H, RAMAMOORTHY P, SHEEHAN J, SMARR L, SMITH CV, SMITH T, SNYDER M, RAPOLE S, SRIVASTAVA S, STANBERRY L, STEWART E, TOPPO S, UETZ P, VERHEGGEN K, VOY BH, WARNICH L, WILHELM SW, YANDL G. Toward more transparent and reproducible omics studies through a common metadata checklist and data publications.

OMICS. 2014 Jan;18(1):10-4.

2014.04. KOLKER E, ÖZDEMIR V, MARTENS L, HANCOCK W, DUMBILL E, ANDERSON N, AYNACIOGLU S, BARANOVA A, CAMPAGNA S, CHEN R, CHOINIÈRE J, DEARTH S, FENG W-C, FERGUSON L, FOX G, GROSSMAN R, HEATH A, HIGDON R, HUTZ MH, JANKO I, JIANG L, JOSHI S, KEL A, KEMNITZ JW, KOHANE IS, KOLKER N, LANCET D, LEE E, LI W, LISITSA A, LLERENA A, MACNEALY-KOCH C, MARSHALL JP, MASUZZO P, MAY A, MIAS G, MONTAGUE E, MOONEY S, NESVIZHSKII A, NORONHA S, OMENN G, RAJASIMHA HK, SHEEHAN J, SMARR L, SMITH C, SMITH

T, SNYDER M, SRIKANTH R, SRIVASTAVA S, STANBERRY L, STEWART E, TOPPO S, UETZ P, VERHEGGEN K, VOY B, WARNICH L, WILHELM S, YANDL G. Towards more transparent and reproducible OMICS studies through a common metadata checklist and data publications.

BIG DATA. 2014; 1 (4):196-201.

2014.05. LAZALDE-RAMOS BP, MARTÍNEZ-FIERRO ML, GALAVIZ-HERNÁNDEZ C, GARZA-VELOZ I, NARANJO MEG, SOSA-MACÍAS M, LLERENA A. CYP2D6 gene polymorphism and predicted phenotypes in eight indigenous groups from northwestern Mexico.

Pharmacogenomics. 2014; 15(3):339-48.

2014.06. DORADO P, PEÑAS-LLEDO EM, LLERENA A. Research Highlights: novel CYP2C9 genetic polymorphisms and assessment of their impact on hydroxylation capacity.

Pharmacogenomics. 2014 Feb;15(3):261-4.

2014.07. PEÑAS-LLEDÓ EM, LLERENA A. CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials.

Br J Clin Pharmacol. 2014 Apr;77(4):673-83.

2014.08. LÓPEZ-TORRES E, SÜVEGES A, PEÑAS-LLEDÓ EM, DOÑA A, DORADO P, LLERENA A, BERCZ R. Liver enzyme abnormalities during antipsychotic treatment: a case report of risperidone-associated hepatotoxicity.

Drug Metabol Drug Interact. 2014 Jun 1;29(2):123-6.

2014.09. LLERENA A, ALVAREZ M, DORADO P, GONZÁLEZ I, PEÑAS-LLEDÓ E, PÉREZ B, COBALEDA J, CALZADILLA LR. Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain.

Pharmacogenomics J. 2014 Jun;14(3):229-34.

2014.10. MAGALHÃES P, ALVES G, LLERENA A, FALCÃO A. Venlafaxine pharmacokinetics focused on drug metabolism and potential biomarkers.

Drug Metabol Drug Interact. 2014 Sep 1;29(3):129-41.

2014.11. DE ANDRÉS F, SOSA-MACÍAS M, LLERENA A. A rapid and simple LC-MS/MS method for the simultaneous evaluation of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 hydroxylation capacity.

Bioanalysis. 2014 Mar;6(5):683-96.

2014.12. OZDEMIR V, ENDRENYI L, AYNACIOĞLU S, BRAGAZZI NL, DANDARA C, DOVE ES, FERGUSON LR, GERACI CJ, HAFEN E, KESIM BE, KOLKER E, LEE EJ, LLERENA A, NACAK M, SHIMODA K, SOMEYA T, SRIVASTAVA S, TOMLINSON B, VAYENA E, WARNICH L, YAŞAR U. Bernard Lerer: Recipient of the 2014 Inaugural Werner Kalow Responsible Innovation Prize in Global Omics and Personalized Medicine (Pacific Rim Association for Clinical Pharmacogenetics).

OMICS. 2014 Apr;18(4):211-21.

2014.13. CÉSPEDES-GARRO C, JIMÉNEZ-ARCE G, NARANJO MEG, BARRANTES R, LLERENA A. CYP2D6 genetic polymorphism among three Costa Rican Populations.

Rev Cost Ric Med Trop 2014. In press

2014.14. PENCHASZADEH VB, ROJAS-MARTINEZ A, LLERENA A. A tribute to josémaría ("chema") cantú.

Genet Mol Biol. 2014 Mar;37(1 Suppl):310-4.

2014.15. HEKIM N, COŞKUN Y, SINAV A, ABOU-ZEID AH, AĞIRBAŞLI M, AKINTOLA SO, AYNACIOĞLU S, BAYRAM M, BRAGAZZI NL, DANDARA C, DERELI T, DOVE ES, ELBEYLİ L, ENDRENYİ L, ERCIYAS K, FARIS J, FERGUSON LR, GÖĞÜŞ F, GÜNGÖR K, GÜRSOY M, GÜRSOY UK, KARAÖMERLIOĞLU MA, KICKBUSCH I, KILIÇ T, KILINÇ M, KOCAGÖZ T, LIN B, LLERENA A, MANOLOPOULOS VG, NAIR B, OZKAN B, PANG T, SARDAŞ S, SRIVASTAVA S, TORAMAN C, USTÜN K, WARNICH L, WONKAM A, YAKICIER MC, YAŞAR U, OZDEMİR V. Translating biotechnology to knowledge-based innovation, peace, and development? Deploy a science peace corps-an open letter to world leaders.

OMICS. 2014 Jul;18(7):415-20.

2014.16. MAGALHÃES P, ALVES G, LLERENA A, FALCÃO A. Clinical drug-drug interactions: focus on venlafaxine.

Drug Metabol Drug Interact. 2014. In press

2014.17. PEÑAS-LLEDÓ E, GUILLAUME S, NARANJO ME, DELGADO A, JAUSSENT I, BLASCO-FONTECILLA H, COURTET P, LLERENA A. A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances.

Pharmacogenomics J. 2014 In press.

2014.18. DORADO P, GALLEGO A, PEÑAS-LLEDÓ E, TERÁN E, LLERENA A. Relationship between the CYP2C9 IVS8-109A>T polymorphism and high losartan hydroxylation in healthy Ecuadorian volunteers.

Pharmacogenomics. 2014 Aug;15(11):1417-21.

2014.19. LLERENA A, NARANJO ME, RODRIGUES-SOARES F, PENAS-LLEDÓ EM, FARIÑAS H, TARAZONA-SANTOS E. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations.

Expert Opin Drug Metab Toxicol. 2014 Nov;10(11):1569-83.

